Cost-effectiveness of community-acquired pneumonia therapy

Authors: Foley, Raymond J; Metersky, Mark L

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 3, Number 6, December 2003 , pp. 749-756(8)

Publisher: Expert Reviews

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Community-acquired pneumonia is a common disease in adults and substantially contributes to morbidity and mortality in the USA and worldwide. Due to the significant costs associated with this disease, there is increasing pressure to evaluate the variation in practices among healthcare providers. The processes of care related to the diagnosis, management and prevention of community-acquired pneumonia are reviewed. Furthermore, the cost-effective strategies for community-acquired pneumonia and the medical evidence that support their usage are outlined.

Keywords: antimicrobial; azithromycin; ceftriaxone; cost; cost-effective; flouroquinolone; guidelines; length of stay; levofloxacin; macrolide; mortality; pneumonia

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737167.3.6.749

Publication date: 2003-12-01

More about this publication?

Expert Review of Pharmacoeconomics & Outcomes Research provides expert commentary on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites